Menu menu
  • Flux RSS
  • Twitter
  • Facebook
  • Google Plus
  • LinkedIn
  • YouTube

2016

Metafora Biosystems and CERBA Healthcare announce (...)

2016

The Cerba HealthCare Group and METAFORA biosystems are to cooperate in the deployment of METAFORA proprietary technology in the field of metabolomics for diagnostics purposes. The technological platform developed by METAFORA enables the evaluation of cells’ energy needs in connection with patients’ health.

  • Lire la suite
  • Articles similaires

Stroke company Acticor Biotech and Mediolanum (...)

2016

Acticor Biotech SAS and Mediolanum farmaceutici S.p.A., today announced that they have entered into a research collaboration agreement for Acticor’s project ACT-017, a humanized antibody Fragment (Fab). Under the terms of the agreement, Mediolanum will co-finance research and development of ACT-017, currently in preclinical development as a potential next generation antithrombotic treatment for acute ischemic (...)

  • Lire la suite
  • Articles similaires

Jean-Marc Grognet succeeds Pierre Tambourin as (...)

2016

Jean-Marc Grognet was confirmed as the new chief executive of Genopole at the general assembly of the Groupement d’intéret public (GIP) Genopole. He will replace Pierre Tambourin, CEO since 1998.

  • Lire la suite
  • Articles similaires

Genopole Young Biotech Award 2016 : Biostart wins (...)

2016

Having convinced the jury unanimously, the company Biostart was named laureate of the sixth edition of the Genopole Young Biotech Award at the awards ceremony held Tuesday 13 December at the Caisse d’Epargne headquarters in Paris. Two of the five finalists also took home special prizes : the project Spiris won the Industrial Potential prize and Unibiome the International Potential prize. Consult the Press Kit (...)

  • Lire la suite
  • Articles similaires

Insect Breeding Innovator Ynsect Raises $15.2m to (...)

2016

Ynsect – the global leader in the mass- scale breeding of insects for the animal feed markets – today announces that it has closed a $15.2m Series B round led by Future Positive Capital, Quadia SA and Bpifrance Ecotechnologies, with participation from existing investors Emertec, Demeter, Vis Vires New Protein Capital and Business Angels. This latest round brings the cumulative amount Ynsect has raised, from private and public sources, to $37m over the last three years – the largest-ever (...)

  • Lire la suite
  • Articles similaires